API
< Back to situation

[REVISION HISTORY]

FDA panel recommends benefits of Grail Galleri test

3 recorded revisions of this situation.

What changed

2026-09-25 21:05 UTC → 2026-10-09 02:23 UTC · added removed

GRAIL, Inc. is undergoing a regulatory review by an moving closer to potential FDA advisory panel regarding approval for its Galleri multi-cancer early detection blood test. The test, intended for adults aged 50 and older, identifies DNA fragments shed by tumor cells to detect multiple types of cancer. While FDA reviewers have reported no major outstanding concerns regarding primary safety analysis, they have tasked test following a recommendation from the Molecular and Clinical Genetics Panel with evaluating whether clinical performance data justifies Devices Committee. On September 23, 2026, the company’s proposed labeling for ‘early’ cancer detection. The panel must determine if voted 7-2 that the test’s benefits outweigh risks such as missed diagnoses or false alarms. Data from the PATHFINDER 2 study indicated a specificity of 99.64% and its risks, while reaching a positive predictive value of 60.3%. Among those with newly diagnosed primary cancers, 53% were in stage 1 or 2, and unanimous 10-0 decision regarding its safety. Despite the test correctly predicted panel’s recommendation, scientific debate persists regarding the cancer’s likely origin in 91.3% test’s clinical utility. Dr. H. Gilbert Welch of cases. On September 23, 2026, the FDA’s Molecular Brigham and Clinical Genetics Devices Committee issued a recommendation Women’s Hospital has argued against approval, stating that the benefits of the Galleri test outweigh primary trial failed to meet its risks for the target population. The committee voted 7-2, with one abstention, in favor main objective of the test’s benefit-risk profile. While reducing late-stage cancer diagnoses. Conversely, Grail CEO Dr. Josh Ofman maintains that the panel reached a unanimous 10-0 decision regarding safety, votes on clinical evidence is robust, noting the test’s effectiveness were test identifies significantly more divided, resulting in a 6-4 split. cancers at earlier stages. Some committee members expressed concerns researchers continue to caution that current data does not definitively prove there is no definitive proof the test reduces overall cancer mortality or qualifies as mortality. Economic factors remain a true ‘early detection’ tool. Although the panel’s recommendation significant hurdle for widespread adoption. The Galleri test currently costs approximately $949 and is nonbinding, it marks primarily an out-of-pocket expense for patients. While a significant milestone toward potential FDA approval. Such approval new US law could facilitate coverage through potentially make FDA-approved tests eligible for Medicare coverage by 2028, broader insurance reimbursement remains uncertain. Analysts estimate the US market for such diagnostic tests could reach between $18 billion and private insurers, moving $30 billion over the test beyond its current status of being primarily available via out-of-pocket payments. next decade.

Versions

  1. 2026-10-09 02:23 UTC FDA panel recommends benefits of Grail Galleri test
  2. 2026-09-25 21:05 UTC FDA panel recommends benefits of Grail Galleri test
  3. 2026-09-24 01:52 UTC FDA panel recommends benefits of Grail Galleri test
  4. 2026-09-23 20:21 UTC FDA review of GRAIL Galleri cancer blood test

Select a version to see what changed compared to the one before it.